Results 1 to 10 of about 5,335 (136)

Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study [PDF]

Frontiers in Medicine
BackgroundPatients with severe or critical coronavirus disease 2019 (COVID-19) remain at a high risk of mortality. Although nirmatrelvir/ritonavir has demonstrated efficacy in non-severe COVID-19 patients with high-risk factors, its effectiveness in ...
Heng Zhao, Heng Zhao, Wanting Meng, Xing Lv, Shaokui Si, Shunjun Wu, Jing Li, Zhigui Cai, Ruoqi Jin, Ling Yang, Chenyao Li, Liqiang Song   +11 more
doaj   +2 more sources

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Antibiotics, 2022
Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related hospitalization or death was observed in patients treated with nirmatrelvir ...
Wen-Chien Ko, Pei‐Jane Tsai, Ching-Chi Lee   +2 more
exaly   +3 more sources

Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System

Infectious Diseases and Therapy
Introduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients nationally. Methods We conducted a retrospective cohort study among
Laura Puzniak, Aisling R Caffrey, Timothy L Wiemken   +2 more
exaly   +2 more sources

A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women [PDF]

Clinical and Translational Science
In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir ...
Jacqueline Gerhart, Narayan Cheruvu, Kathleen Pelletier, Kyle Matschke, Haihong Shi, Josué Kunjom Mfopou, Jennifer Hammond, Ravi Shankar P. Singh   +7 more
doaj   +2 more sources

Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China [PDF]

BMJ Open Respiratory Research
Background While simnotrelvir-ritonavir and nirmatrelvir-ritonavir, the oral antiviral agents targeting the 3C-like proteases, are widely used in China, robust data on their appropriate use remain limited in hospitalised patients.
Hui Zhang, Hui Yang, Yi Zhang, Jia Li, Han Wu, Xintong Zhang, Zhuoling An, Yuezhen Zhu, Chunguo Jiang, Wanying Chen   +9 more
doaj   +2 more sources

Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study [PDF]

BMC Infectious Diseases
Background COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir ...
Wen-Kuang Lin, Shwu-Jiuan Lin, Yu-Hui Chang, Fu-Der Wang, Phung-Anh Nguyen, Phan Thanh Phuc, Whitney Burton, Nguyen Thi Kim Hien, Chia-Chieh Lin, Carlos Shu-Kei Lam, To-Chi Ha, Christine Y. Lu, Chih-Wei Huang, Hsuan-Chia Yang, Shiue-Ming Lin, Chieh Yang, Li-Hsuan Wang, Jason C. Hsu   +17 more
doaj   +2 more sources

Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions

Infectious Diseases and Therapy
Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of ...
Abby E. Rudolph, Farid Khan, John M McLaughlin   +2 more
exaly   +2 more sources

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients

Scientific Reports
Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain.
Hawra Ali Hussain Alsayed, Fatemeh Saheb Sharif-Askari, Rabih Halwani   +2 more
exaly   +2 more sources

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19 [PDF]

Immunity, Inflammation and Disease
Background and Aim Simnotrelvir/ritonavir and nirmatrelvir/ritonavir are major treatments for COVID‐19, but their comparative efficacy and safety, especially in patients with moderate to severe COVID‐19, remain unclear.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
doaj   +2 more sources

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Tim Conrad, Sydney Paltra
exaly   +3 more sources